Goldman Sachs
EGRX

Goldman Sachs’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Goldman Sachs’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31,495
Closed -$117K – 6395
2024
Q3 		$117K Sell
31,495
-47,598
-60% -$227K ﹤0.01% 5554
2024
Q2 		$443K Sell
79,093
-98,714
-56% -$430K ﹤0.01% 4896
2024
Q1 		$932K Sell
177,807
-16,017
-8% -$87.9K ﹤0.01% 4395
2023
Q4 		$1.01M Buy
193,824
+32,571
+20% +$322K ﹤0.01% 4380
2023
Q3 		$2.54M Sell
161,253
-53,977
-25% -$970K ﹤0.01% 3577
2023
Q2 		$4.18M Buy
215,230
+45,684
+27% +$1.08M ﹤0.01% 3254
2023
Q1 		$4.81M Buy
169,546
+27,652
+19% +$821K ﹤0.01% 3109
2022
Q4 		$4.15M Buy
141,894
+32,217
+29% +$1.02M ﹤0.01% 3334
2022
Q3 		$2.9M Sell
109,677
-55,905
-34% -$2.05M ﹤0.01% 3635
2022
Q2 		$7.36M Sell
165,582
-12,724
-7% -$584K ﹤0.01% 2786
2022
Q1 		$8.82M Buy
178,306
+70,438
+65% +$3.38M ﹤0.01% 2816
2021
Q4 		$5.49M Buy
107,868
+792
+0.7% +$41K ﹤0.01% 3313
2021
Q3 		$5.97M Sell
107,076
-90,686
-46% -$4.46M ﹤0.01% 3203
2021
Q2 		$8.46M Buy
197,762
+60,540
+44% +$2.5M ﹤0.01% 2852
2021
Q1 		$5.73M Sell
137,222
-10,947
-7% -$508K ﹤0.01% 3012
2020
Q4 		$6.9M Sell
148,169
-18,697
-11% -$874K ﹤0.01% 2751
2020
Q3 		$7.09M Buy
166,866
+45,523
+38% +$1.99M ﹤0.01% 2616
2020
Q2 		$5.82M Sell
121,343
-205,950
-63% -$10.3M ﹤0.01% 2684
2020
Q1 		$15.1M Buy
327,293
+189,120
+137% +$9.49M 0.01% 1736
2019
Q4 		$8.3M Buy
138,173
+70,233
+103% +$4.19M ﹤0.01% 2570
2019
Q3 		$3.84M Sell
67,940
-38,412
-36% -$2.16M ﹤0.01% 3059
2019
Q2 		$5.92M Sell
106,352
-24,508
-19% -$1.28M ﹤0.01% 2732
2019
Q1 		$6.61M Sell
130,860
-31,597
-19% -$1.41M ﹤0.01% 2756
2018
Q4 		$6.55M Sell
162,457
-5,477
-3% -$282K ﹤0.01% 2666
2018
Q3 		$11.6M Buy
167,934
+47,819
+40% +$3.63M ﹤0.01% 2335
2018
Q2 		$9.09M Buy
120,115
+17,671
+17% +$1.11M ﹤0.01% 2482
2018
Q1 		$5.4M Sell
102,444
-6,413
-6% -$373K ﹤0.01% 2831
2017
Q4 		$5.82M Buy
108,857
+26,251
+32% +$1.46M ﹤0.01% 2887
2017
Q3 		$4.93M Sell
82,606
-22,175
-21% -$1.34M ﹤0.01% 3158
2017
Q2 		$8.27M Sell
104,781
-32,256
-24% -$2.64M ﹤0.01% 2653
2017
Q1 		$11.4M Buy
137,037
+96,536
+238% +$7.18M ﹤0.01% 2314
2016
Q4 		$3.21M Buy
40,501
+13,555
+50% +$985K ﹤0.01% 3430
2016
Q3 		$1.89M Buy
26,946
+12,096
+81% +$670K ﹤0.01% 3883
2016
Q2 		$576K Sell
14,850
-54,362
-79% -$2.26M ﹤0.01% 4723
2016
Q1 		$2.8M Buy
69,212
+61,390
+785% +$3.9M ﹤0.01% 3197
2015
Q4 		$694K Buy
7,822
+6,798
+664% +$537K ﹤0.01% 4639
2015
Q3 		$76K Sell
1,024
-17,074
-94% -$1.42M ﹤0.01% 6627
2015
Q2 		$1.46M Buy
18,098
+8,259
+84% +$538K ﹤0.01% 4166
2015
Q1 		$412K Buy
+9,839
New +$279K ﹤0.01% 5336

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Goldman Sachs's EGRX Position: Q4 2024 in Review

Goldman Sachs sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 31,495 shares — an estimated $117K sold.

Goldman Sachs first reported a position in EGRX in Q1 2015 and held it in 39 quarters. The position peaked at $15.1M in Q1 2020. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Goldman Sachs reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Goldman Sachs sold 31,495 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $117K.
  • Goldman Sachs first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 39 quarters.
  • Goldman Sachs's Eagle Pharmaceuticals, Inc. position peaked at $15.1M in Q1 2020.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Goldman Sachs's 13F filing for Q4 2024, filed 11 Feb 2025.